Empowering Policy: Precision Healthcare in EU

This lecture explores the transition from traditional histology-based models to agnostic models in oncology, focusing on the evidence from precision medicine programs in the European Union.

Learning Objective:
Understand the shift in oncology towards precision medicine, including the role of genomic profiling in guiding targeted therapies.

The second part of this lecture delves into the challenges faced in genomic oncology, including the interpretation of vast genomic data and the integration of molecular findings into clinical practice. It also highlights innovative approaches such as molecular tumor boards and the AURORA study.

Learning Objective:
Explore the complexities of genomic oncology and learn about innovative solutions to overcome challenges in translating genomic data into clinical insights.

The final section of the lecture discusses global perspectives on precision oncology, addressing issues such as racial and ethnic disparities in genomic profiling and the need for international collaboration. It also outlines future directions, including the importance of accessible precision medicine programs worldwide.

Learning Objective:
Gain insights into the global landscape of precision oncology and understand the importance of addressing disparities and fostering international collaboration for the advancement of precision medicine.

This lecture explores the current landscape and future directions of personalised precision medicine in oncology, focusing on the challenges and strategies for advancing adoption and implementation across Europe.

Learning objective:
Understand the importance of collaboration, harmonisation, and quality control in driving the adoption of personalised precision medicine in oncology, and identify key strategies to overcome barriers and promote equitable access to testing and treatment.

Dr. Paul Hofman discusses key developments and challenges in personalized precision medicine for thoracic oncology, emphasizing the importance of on-site testing, education, cost equity, and harmonization.

Learning objectives:
1. Understand the latest advancements in personalized precision medicine for thoracic oncology.
2. Identify challenges in implementing these advancements.
3. Explore strategies for overcoming them to improve patient care and outcomes.

Dr. Paul Hofman reflects on a decade of progress in precision oncology, highlighting the need for robustness, quality control, and harmonization in predictive biomarker testing. He emphasizes the importance of addressing key issues such as harmonization, standardization, and reimbursement to propel the field forward together.

Learning objectives:
1. Understand the challenges and successes in precision oncology over the past decade.
2. Recognize the importance of quality control and harmonization in predictive biomarker testing.
3. Identify strategies for advancing precision oncology through collaboration and education.

NGS and liquid biopsy go hand-in-hand, but they are by no means synonymous and both entail complex methodologies that are constantly evolving and improving. In this first video, we will provide an overview of the central role of molecular profiling in precision oncology, cover the fundamentals of next-generation sequencing technology and its applications, and then introduce the liquid biopsy and the role of ctDNA in cancer care. The goal of this video is to help the viewer understand what the goal of precision oncology is, how ctDNA biomarkers can be used as a tool to implement precision oncology and how NGS is currently the best methodology at hand to detect and measure these biomarkers.

In this second video, we will demonstrate the current clinical application of liquid biopsy in oncology practice and separate these use cases from those that still under development or are not yet ready for the clinic. We will cover assay selection and other considerations as well as regulatory approvals and indications. Here, we will especially highlight the advanced cancer use case and show how ctDNA is used to guide treatment decisions, including matching alterations to therapies or for monitoring response and describe the central role and infrastructure of the molecular tumor board. We will also cover the rise of complex biomarkers such as tumor fraction, MSI status and bTMB and how this information requires expert interpretation prior to clinical integration. We will also highlight the future direction of cfDNA testing, including application in early disease and screening for cancer.

Precision oncology is complex and requires know-how across multiple knowledge domains. In this video, we will focus on current bottlenecks in the clinical implementation of liquid biopsy, such as logistical, regional and reimbursement issues, dealing with negative results, and, primarily, the formal training that is required from assay selection to bioinformatics to variant interpretation in order to successfully carry out a local liquid biopsy program.

This lecture explores the objectives and impact of the 1+ Million Genomes initiative in enhancing disease prevention, personalized treatments, and research support.

Learning objective:
Understand the goals of the initiative, its role in improving healthcare outcomes, and the importance of secure genomic data access.

In this part, dr. Jasmina Koeva examines the B1MG project's efforts to extend data sharing beyond the 1+ Million Genomes initiative and enable access to additional genomic resources.

Learning objective:
Learn about the B1MG project's objectives, its role in facilitating long-term data sharing, and its implications for healthcare innovation.

In concluding remarks, dr. Koeva talks about the Genome of Europe project, which aims to create a high-quality European network of genomic reference cohorts to benefit personalized healthcare and research.

Learning objective:
Understand the goals of the Genome of Europe project, its contribution to European healthcare innovation, and the importance of cross-country collaboration in genomic research.

This lecture explores the value of precision medicine (PM) in addressing rare diseases within the European Union (EU). It delves into the intricacies of rare diseases, the regulatory landscape, diagnostic challenges, treatment options, and the importance of European Reference Networks (ERNs) in improving patient outcomes.

Learning Objective:
Understand the definition and regulatory framework surrounding rare diseases within the EU, explore the challenges and inequalities faced by rare disease patients, including diagnostic delays and limited treatment options, assess the role of European Reference Networks (ERNs) in facilitating collaboration, improving access to specialized care, and addressing geographical disparities in rare disease management.

This session focuses on the epidemiology and challenges of rare cancers within the EU, examining disparities in survival rates, access to orphan drugs, and geographical variations in healthcare outcomes. It also discusses strategies for improving early diagnosis, treatment access, and collaboration among member states.

Learning Objective:
Understand the epidemiological landscape of rare cancers and associated disparities in survival rates, evaluate the impact of geographical inequalities on access to orphan drugs and specialized cancer care, explore policy initiatives and collaborative efforts aimed at addressing inequities in rare cancer diagnosis, treatment, and patient outcomes.

In this final part, prof. Birute Tumiene highlights the importance of integrating European Reference Networks (ERNs) into national healthcare systems to improve rare disease diagnosis, treatment, and patient outcomes. It discusses legal, organizational, and informational measures needed for successful integration, as well as the role of ERNs in promoting cross-border healthcare collaboration.

Learning Objectives:
Understand the significance of integrating ERNs into national healthcare systems for improving rare disease management, identify the legal, organizational, and informational challenges associated with ERN integration, explore strategies and best practices for promoting collaboration between ERNs and national healthcare systems to enhance patient care and outcomes.